News | February 17, 2025
Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
No safety signals related to the vaccine candidate were identified
No safety signals related to the vaccine candidate were identified
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Subscribe To Our Newsletter & Stay Updated
